Sponsored Content
Manufacturing in a Tariff-Driven World: Why Commercial Biologics Capacity Must Align with Market Demand
As trade policy, regulatory scrutiny, and capital discipline reshape biologics development, sponsors are rethinking where and how commercial manufacturing is secured. Bora Biologics’ recent U.S. expansion and validated 2,000L scale-up reflect a broader shift toward demand-aligned, inspection-ready commercial capacity in the markets where products will ultimately be supplied.
The New Definition of Capacity
In biologics manufacturing, capacity used to mean stainless steel volume and available cleanroom space. Today, it means something more complex.
Sponsors evaluating CDMO partners are weighing geography alongside scale. They are assessing tariff exposure, regulatory familiarity, inspection history, and the probability of late-stage technology transfer disruption. As global trade policies evolve and geopolitical tensions influence supply chains, where a product is manufactured has become a strategic decision—particularly for molecules targeting U.S. and European markets. At the same time, biologics pipelines are…
